Aktuelle standards der behandlung schizophrener erkrankungen

Psychopharmakotherapie

Volumn 3, Issue 2, 1996, Pages 51-56

  Möller, Hans Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CLOZAPINE; DIAZEPAM; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL; LEVOMEPROMAZINE; LITHIUM SALT; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; VALPROIC ACID; ZOTEPINE;

HUMAN; NEGATIVE SYNDROME; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; SOCIOTHERAPY;

EID: 0042099643     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Baldessarini RJ, Cohen BM,Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988;45:79-91.
2. Baldessarini RJ, Fleischhacker WW, Sperk G. Pharmakotherapie in der Psychiatrie. Stuttgart: Thieme, 1991.
3. Barnes TR, Curson DA. Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf 1994;10:464-79.
4. Benkert O, Hippius H. Psychiatrische Pharmakotherapie. Berlin: Springer-Verlag, 1996.
5. Bitter I, Volavka J, Scheurer J. The concept of the neuroleptic threshold: an update. J Clin Psychopharmacol 1991;11:28-33.
6. Brenner HD, Hodel B, Kube G, Roder V. Kognitive Therapie bei Schizophrenen: Problemanalyse und empirische Ergebnisse. Nervenarzt 1987;58:72-83.
7. Buchkremer G, Schulze-Mönking H, Holle R, Hornung WP. The impact of therapeutic relatives' groups on the course of illness of schizophrenic patients. Eur Psychiatry 1995;10: 17-27.
8. Carpenter WT, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr Bull 1985;11:440-52.
9. Carpenter WT, Stevens JH, Rey AC. Early intervention vs. continuous pharmacotherapy in schizophrenia. Psychopharmacol Bull 1992; 18:21-3.
10. Dahl SG. Plasma level monitoring of antipsychotic drugs. Clinical utility. Clin Pharmacokin 1986;11:36-61.
11. Deister A,MöllerHJ.Schizophrenie.SpringerVerlag. Im Druck.
12. Eckman TA, Wirshing WC, Marder SR, Liberman RP, et al. Technique for training schizophrenic patients in illness self-management: a controlled trial. Am J Psychiatry 1992;149: 1549-55.
13. Fleischhacker WW, Meise U, Gunther V, Kurtz M. Compliance with antipsychotic treatment, influence of side-effects. Acta Psychiatr Scand 1994;89(Suppl 382): 11-5.
14. Gaebel W, Frick U, Köpeke W, Linden M, et al. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?. Br J Psychiatry 1993;163(Suppl 21):8-12.
15. Gardos G. Are antipsychotic drugs interchangeable? J Nerv Ment Dis 1974;159:343-8.
16. Goodnick PJ, Meltzer HY. Treatment of schizoaffective disorders. Schizophr Bull 1984; 10:30-48.
17. Herz MI, Glazer WM, Mostert MAe. Intermittent vs maintenance medication in schizophrenia: two-year results. Arch Gen Psychiatry 1991;48:333-9.
18. Hinterhuber H, Haring C. Unerwünschte Wirkungen, Kontraindikationen, Überdosierungen, Intoxikation. In: Riederer P, Laux G, Pöldinger W, Hrsg. Neuro-Psychopharmaka, Bd. 4 Neuroleptika. Wien: Springer, 1992:102-21.
19. Hirsch SR, Weinberger DR, editors. Schizophrenia. Oxford: Blackwell Science, 1995.
20. Hirsch SR, Jolley AG, Manchanda R, McRink A. Early intervention medication as an alternative to continuous depot treatment in schizophrenia: Preliminary report. In: Strauss J, Boker W, Brenner HD, editors. Psychosocial treatment of schizophrenia. Bern: Hubcr, 1987:63.
21. Hogarty GE, Anderson CM, Reiss DJ, Komblith SJ, et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. I. One-year effects of a controlled study on relapse and expressed emotion. Arch Gen Psychiatry 1986;43:633-42.
22. Hogarty GE, Schooler NR, Ulrich R, Mussare F, et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979;36:1283-94.
23. Johnson DAW. Observations on the dose regimens of fluphenazine decanoate in maintenance therapy of schizophrenia. Br J Psychiatry 1975;126:457-61.
24. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993;19:287-302.
25. Kane JM, Rifkin A, Woerner M,Reardon G,et al. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry 1983;40: 893-6.
26. Kane JM, Woerner M, Borenstein M, Wegner J, et al. Integrating incidence and prevalence of tardive dyskincsia. Psychopharmacol Bull 1986;22:254-8.
27. Kane J, Honigfeld G, Sawyer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-96.
28. Kane J, Möller HJ, Awouters F. Serotonergic mechanism in antipsychotic treatment. New York: Marcel Dekker. Im Druck.
29. Kinon BJ, Kane JM, Johns C, Perovich R, et al. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 1993;29: 309-14.
30. Kissling W. Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr Scand 1994;89(Suppl 382): 16-24.
31. Liberman RP, Mueser KT, Wallace CJ. Social skills training for schizophrenic individuals at risk for relapse. Am J Psychiatry 1986;143: 523-6.
32. Lieberman J, Jody D, Geisler S, Alvir J, et al. Time course and biological correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993;50:369-76.
33. Marder SR, Van Putten T, Mintz J, Lebell M,et al. Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome. Arch Gen Psychiatry 1987;44: 518-21.
34. McEvoy JP,Hogarty GE,Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991;48:739-45.
35. Meltzer HY. Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Arch Gen Psychiatry 1989;46:672.
36. Meltzer HY. Treatment of the neuroleptic nonresponsive schizophrenic patient. Schizophr Bull 1992;18:515-42.
37. Möller HJ. Neuroleptische Langzeittherapie schizophrener Erkrankungen. In: Heinrich K, Hrsg. Leitlinien neuroleptischer Therapie. Berlin: Springer-Verlag, 1990:97-115.
38. Möller HJ. Neuroleptische Rezidivprophylaxe und Langzeitbehandlung schizophrener Psychosen. In: Riederer P, Laux G, Pöldinger W, Hrsg. Neuro-Psychopharmaka, Bd. 4 Neuroleptika. Wien: Springer-Verlag, 1992:153-68.
39. Möller HJ. Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. Eur Neuropsychopharmacol 1993;3:1-11.
40. Möller HJ. Medikamentöse Rezidivprophylaxe schizophrener Erkrankungen. In: Möller HJ, Hrsg. Therapie psychiatrischer Erkrankungen. Stuttgart: Enke-Verlag, 1993;200-11.
41. Möller HJ. Extrapyramidal side effects of neuroleptic medication: focus on risperidone. Int Acad Biomed Drug Res. 1995;142-51.
42. Möller HJ, Morin C. Behandlung schizodepressiver Syndrome mit Antidepressiva. In: Mameros, Hrsg. Schizoaffektive Psychosen. Diagnose, Therapie und Prophylaxe. Berlin: Springer, 1989:159-78.
43. Möller HJ, Rao ML. Negative symptoms of schizophrenia: Methodological issues, biochemical findings and efficacy of neuroleptic treatment. In: Ackenheil M, Bondy B, Engel R, Ermann M, et al., editors. Implications of psychopharmacology to psychiatry. Biological, nosological, and therapeutical concepts. Berlin: Springer, 1996:158-78.
44. Möller HJ, von Zerssen D. Der Verlauf schizophrener Psychosen unter den gegenwärtigen Behandlungsbedingungen. Berlin: Springer, 1986.
45. Möller HJ, Kissling W, Lang C, Doerr P, et al. Efficacy and side effects of haloperidol in psychotic patients: oral versus intravenous administration. Am J Psychiatry 1982;139:1571-5.
46. Möller HJ, Müller H, Borison RL, Schooler NR, et al. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenia patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995;245:45-9.
47. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-35.
48. Prusoff BA, Williams DH, Weissman MM, Astrachan B A. Treatment of secondary depression in schizophrenia. Arch Gen Psychiat 1979;36:569-75.
49. Reardon GT, Rifkin A, Schwartz A, Myerson A, et al. Changing pattern of neuroleptic dosage over time. Am J Psychiatry 1989;146: 726-9.
50. Rifkin A, Doddi S, Karajgi B, Borenstein M, et al. Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 1991;48:166-70.
51. Sagatovic M, Meltzer HY. The effect of shortterm electroconvulsive treatment plus neuroleptic in treatment-resistant schizophrenia and schizoaffective disorder. Convuls Ther 1993; 9:167-75.
52. Schulz SC, Kahn EM, Baker RW, Conley RR. Lithium and Carbamazepine. Augmentation in treatment-refractory schizophrenia. In: Angrist B, Schulz SC, editors. The neuroleptic-nonresponsive patient: Characterization and treatment. Washington: American Psychiatric Press Inc., 1990:111-36.
53. Shalev A, Hermesh H, Rothberg J, Munitz H. Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatr Scand 1993;87:86-91.
54. Siris SG. Depression and schizophrenia. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. Oxford: Blackwell Science, 1995: 128-45.
55. Siris SG, Kammen vDP, Docherty JP. Use of antidepressant drugs in schizophrenia. Arch Gen Psychiatry 1978;35:1368-77.
56. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990;47:754-8.
57. Vaughn CE, Snyder KS, Freeman W, Jones S, et al. Family factors in schizophrenia relapse: a replication. Schizophr Bull 1982;8:425-6.
58. Wing JK. Eine praktische Grundlage für die Soziotherapie bei Schizophrenie. In: Huber G, Hrsg. Therapie, Rehabilitation und Prevention schizophrener Erkrankungen. Stuttgart: Schattauer-Verlag, 1976.